Mental and Behavioral Health

Researchers aimed to estimate the impact of using behavioral science principles within communication intended for hypertension medication adherence.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

Patients included in the study were aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD).

Researchers conduct a scoping review to update and determine what the best available options are for treating patients with skin-picking disorder.

In children aged 5 to 17 with skin disorders, researchers explore the risk of developing psychosocial comorbidities, sleep disturbances, and common related symptoms.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

Investigators note that the long-term effects of attention deficit/hyperactivity disorder (ADHD) medication for children remain lacking.

Patients with psychosis, depression, and anxiety exhibit higher rates of vaccine hesitancy.

However, the results show that there was an improvement of symptom scores, although they were not significant.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

A new study found that GLP-1s were not associated with an increased risk of suicidal ideation, self-harm, or suicide compared to DPP-4 and SGLT-2 inhibitors.

The updated label also includes alternative injection sites, such as the abdomen, thigh, buttock, or back of the upper arm.

The study authors report that long-term daily administration of amlodipine induced behavioral changes in the rats during their open field test.

Pharmacists who participated in the mental health first aid training had better understanding of mental health conditions and increased confidence and skills in mental health intervention.

Taking once-weekly subcutaneous semaglutide does not increase depression symptoms or suicidal ideation in patients with obesity.

Researchers analyzed overall prescription stimulant dispensing trends among US children from 2017 to 2023.

The approval makes Johnson and Johnson’s esketamine nasal spray the first and only monotherapy for the treatment of major depressive disorder in adult patients.

A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.

Nina Vadiei, PharmD, BCPP, discusses some of the challenges she faces working with forensic patients who have been charged with a crime and have severe mental illness.

Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.

The drug is also approved to treat schizophrenia and bipolar depression.

Researchers addressed the gut-first hypothesis of Parkinson disease by identifying how mucosal damage impacts risk of development.

Normalizing conversations around mental health in older adult populations can improve outcomes.

A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

The partnership will provide tools to address both patient and pharmacist well-being amid the current mental health crisis.

The COVID-19 pandemic negatively impacted mental health in young people, and additional targeted mental health resources are needed.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.